Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist

Connie L Erickson-Miller, Evelyne Delorme, Shin-Shay Tian, Christopher B Hopson, Amy J Landis, Elizabeth I Valoret, Teresa S Sellers, Jon Rosen, Stephen G Miller, Juan I Luengo, Kevin J Duffy, Julian M Jenkins, Connie L Erickson-Miller, Evelyne Delorme, Shin-Shay Tian, Christopher B Hopson, Amy J Landis, Elizabeth I Valoret, Teresa S Sellers, Jon Rosen, Stephen G Miller, Juan I Luengo, Kevin J Duffy, Julian M Jenkins

Abstract

Eltrombopag is a first-in-class, orally bioavailable, small-molecule, nonpeptide agonist of the thrombopoietin receptor (TpoR), which is being developed as a treatment for thrombocytopenia of various etiologies. In vitro studies have demonstrated that the activity of eltrombopag is dependent on expression of TpoR, which activates the signaling transducers and activators of transcription (STAT) and mitogen-activated protein kinase signal transduction pathways. The objective of this preclinical study is to determine if eltrombopag interacts selectively with the TpoR to facilitate megakaryocyte differentiation in platelets. Functional thrombopoietic activity was demonstrated by the proliferation and differentiation of primary human CD34(+) bone marrow cells into CD41(+) megakaryocytes. Measurements in platelets in several species indicated that eltrombopag specifically activates only the human and chimpanzee STAT pathways. The in vivo activity of eltrombopag was demonstrated by an increase of up to 100% in platelet numbers when administered orally (10 mg/kg per day for 5 days) to chimpanzees. In conclusion, eltrombopag interacts selectively with the TpoR without competing with Tpo, leading to the increased proliferation and differentiation of human bone marrow progenitor cells into megakaryocytes and increased platelet production. These results suggest that eltrombopag and Tpo may be able to act additively to increase platelet production.

Figures

Figure 1
Figure 1
Structure of eltrombopag, an orally bioavailable thrombopoietin receptor agonist.
Figure 2
Figure 2
Cell-based STAT activation. (A): Representative gene activity of eltrombopag on BAF3/interferon regulatory factor (IRF)-1 cells transfected with and without the thrombopoietin receptor (TpoR). (B): Gene activity of eltrombopag and recombinant human thrombopoietin (rhTpo) on 32D-mpl cells transfected with the megakaryocyte-specific glycoprotein IIb promoter. Reprinted from Duffy KJ, Erickson-Miller CL. The discovery of eltrombopag, an orally bioavailable TpoR agonist. In: Metcalf BW, Dillon S, eds. Target Validation in Drug Discovery. Burlington, MA: Academic Press, 2007:241–254, with permission.
Figure 3
Figure 3
Signal transduction induced by eltrombopag. (A): Eltrombopag demonstrated activity on human and chimpanzee (but not other species) platelets by signaling transducers and activators of transcription (STAT) electrophoretic mobility shift assay. Similar kinetics of (B) phospho-STAT5 and (C) mitogen-activated protein kinase (MAPK) expression were detected by Western blot of eltrombopag- or recombinant human thrombopoietin (rhTpo)-treated N2C-Tpo cell lysates. (D): STAT5 activation was also detected in megakaryocytes derived from CD34+ cells. (A, B): Reprinted from Duffy KJ, Erickson-Miller CL. The discovery of eltrombopag, an orally bioavailable TpoR agonist. In: Metcalf BW, Dillon S, eds. Target Validation in Drug Discovery. Burlington, MA: Academic Press, 2007:241–254, with permission.
Figure 4
Figure 4
Proliferation and differentiation induced by eltrombopag. (A): Proliferation of BAF3/hTpoR cells induced by eltrombopag after 48 hours of treatment; the dotted line represents the activity of cells treated with 100 ng/ml of recombinant human thrombopoietin. OD, optical density. (B): Representative example of megakaryocyte differentiation of CD34+ cells after 10 days of eltrombopag treatment; similar results were obtained with six independent marrow samples. Panel (B) was reprinted from Duffy KJ, Erickson-Miller CL. The discovery of eltrombopag, an orally bioavailable TpoR agonist. In: Metcalf BW, Dillon S, eds. Target Validation in Drug Discovery. Burlington, MA: Academic Press, 2007:241–254, with permission.
Figure 5
Figure 5
Additive effects of eltrombopag and rhTpo. (A): Proliferation, as measured by thymidine incorporation, of N2C-Tpo cells by eltrombopag (0.003–3 μM) in combination with recombinant human thrombopoietin (rhTpo; 1–100 ng/ml). (B): Activation of caspase-3 and caspase-7 by eltrombopag (0–3 μM) in combination with rhTpo (0–100 ng/ml) in N2C-Tpo cells.
Figure 6
Figure 6
Increase in platelet counts in chimpanzees treated orally with eltrombopag for 5 days at 10 mg/kg per day (solid lines; n = 3) or vehicle (dotted lines, n = 2). Data are expressed as the fold increase of each animal over its baseline platelet count. Reprinted from Duffy KJ, Erickson-Miller CL. The discovery of eltrombopag, an orally bioavailable TpoR agonist. In: Metcalf BW, Dillon S, eds. Target Validation in Drug Discovery. Burlington, MA: Academic Press, 2007:241–254, with permission.

References

    1. Paquette RL. Diagnosis and management of aplastic anemia and myelodysplastic syndrome. Oncology (Williston Park) 2002;16(suppl 10):153–161.
    1. Stevens W, Koene H, Zwaginga JJ, et al. Chronic Idiopathic Thrombocytopenic purpura: Present strategy, guidelines and new insights. Neth J Med. 2006;64:356–363.
    1. Tijssen MR, van der Schoot CE, Voermans C, et al. Clinical approaches involving thrombopoietin to shorten the period of thrombocytopenia after high-dose chemotherapy. Transfus Med Rev. 2006;20:283–293.
    1. Giannini EG. Review article: Thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther. 2006;23:1055–1065.
    1. Bordin G, Ballare M, Zigrossi P, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: A direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol. 1995;13(suppl 13):S39–S43.
    1. Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietThe primary regulator of platelet production. Oncogene. 2002;21:3359–3367.
    1. Kuter DJ, Begley CG. Recombinant human thrombopoietBasic biology and evaluation of clinical studies. Blood. 2002;100:3457–3469.
    1. Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett. 1995;374:48–52.
    1. Drachman JG, Millet KM, Kaushansky K. Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem. 1999;274:13480–13484.
    1. Rojnuckarin P, Drachman JG, Kaushansky K. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: Role in endomitosis. Blood. 1999;94:1273–1282.
    1. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77:1117–1124.
    1. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369:533–538.
    1. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369:568–571.
    1. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994;369:565–568.
    1. Wendling F, Maraskovsky E, Debili N, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature. 1994;369:571–574.
    1. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241–3248.
    1. Erickson-Miller CL, DeLorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005;33:85–93.
    1. Duffy KJ, Darcy MG, Delorme E, et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J Med Chem. 2001;44:3730–3745.
    1. Duffy KJ, Shaw AN, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics. J Med Chem. 2002;45:3573–3575.
    1. Duffy KJ, Price AT, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics. J Med Chem. 2002;45:3576–3578.
    1. Erickson-Miller C, DeLorme E, Iskandar M, et al. Species specificity and receptor domain interaction of a small molecule TpoR agonist. Blood. 2004;104:2909.
    1. Nakamura T, Miyakawa Y, Miyamura A, et al. A novel nonpetidyl human c-Mpl activator stimulates human megakaryocytopoiesis and thrombosis. Blood. 2006;107:4300–4307.
    1. Kim M-J, Park SH, Opella SJ, et al. NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains. J Biol Chem. 2007;282:14253–14261.
    1. Erhardt J, Tapley P, Erickson-Miller C. A low molecular weight, orally active TpoR agonist, SB-497115, does not prime platelets for activation or agonist-induced aggregation in vitro. Exper Hematol. 2005;33(1) suppl:365.
    1. Jenkins JM, Williams D, Deng Y, et al. Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109:4739–4741.
    1. Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood. 1996;88:511–521.
    1. Harker LA, Roskos LK, Marzec UM, et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood. 2000;95:2514–2522.
    1. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237–2247.
    1. Kantarjian HM, Giles FJ, Fenaux P, et al. Evaluating safety and efficacy of AMG 531 for the treatment of thrombocytopenic patients with myelodysplastic syndrome (MDS): Preliminary results of a phase 1/2 study. J Clin Oncol. 2007;25(18) suppl:7032.
    1. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227–2236.
    1. Duffy KJ, Erickson-Miller CL. The discovery of eltrombopag, an orally bioavailable TpoR agonist. In: Metcalf BW, Dillon S, editors. Target Validation in Drug Discovery. Burlington, MA: Academic Press; 2007. pp. 241–254.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe